Collagenase Clostridium Histolyticum
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Collagenase Clostridium Histolyticum
- Collagenase Clostridium Histolyticum: From Localized Collagen-Degrading Therapy to Primary Release Disorder of Platelets
Collagenase Clostridium Histolyticum: From Localized Collagen-Degrading Therapy to Primary Release Disorder of Platelets
One-Sentence Summary
Collagenase clostridium histolyticum is an enzyme that breaks down collagen and is marketed in the US as a locally applied product (Santyl ointment). The TxGNN model predicts it may be effective for primary release disorder of platelets, but 0 clinical trials and 0 publications support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the license data (the Evidence Pack notes Dupuytren’s contracture as a marketed indication under Xiaflex/Xiapex) |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (listed as BLA101995) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, collagenase clostridium histolyticum is a bacterial collagenase preparation that cleaves type I and III collagen. This action is used in locally applied and locally injected products.
A primary release disorder of platelets is an intrinsic defect in platelet secretion. The link to this drug appears to be network proximity in the knowledge graph (platelet-collagen signaling), not a therapeutic mechanism. A locally administered collagen-degrading enzyme has no established role in correcting a platelet secretion defect.
The high score should therefore be read as a likely knowledge-graph artifact, not a credible repurposing signal. Degrading collagen could also, in theory, work against hemostasis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA101995 | COLLAGENASE SANTYL (Smith & Nephew, Inc.) | Ointment | Not listed in the record |
Safety Considerations
Please refer to the package insert for safety information.
The prediction rationale also notes that the product’s labeling contains bleeding-related warnings. Use in a bleeding or platelet disorder would therefore raise a safety concern. This is not confirmed by the safety data in the Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or preclinical support and no plausible mechanism, and it is probably a knowledge-graph artifact. There is also a theoretical bleeding-related safety concern in this patient population.
Two other predictions in the same list are worth noting:
- Ledderhose disease (plantar fibromatosis) is the only genuine repurposing candidate, at evidence level L4. It is mechanistically plausible because it is biologically close to Dupuytren’s disease, but the evidence is limited to three case reports.
- Palmar fibromatosis (Dupuytren’s contracture) has the strongest evidence (L1, including Phase 3 trials and a 2024 randomized comparison with fasciectomy). It appears to be an already-approved indication, so it is not a true repurposing finding. The empty original-indication field appears to be a data gap.
To proceed, the following is needed:
- The US package insert warnings and contraindications
- Detailed mechanism of action data (MOA)
- A corrected original-indication record for this drug
- For Ledderhose disease, a prospective study or controlled trial of collagenase
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.